Thu.Dec 28, 2023

article thumbnail

What Mickey Mouse Lapsing into the Public Domain Means

Plagiarism Today

In just a few days, the first appearance of Mickey Mouse lapses into the public domain. Here's what it really means to other creators. The post What Mickey Mouse Lapsing into the Public Domain Means appeared first on Plagiarism Today.

article thumbnail

Top Tips for Avoiding Trademark Scams

Erik K Pelton

The following is an edited transcript of my video Top Tips for Avoiding Trademark Scams No matter how many times I speak, post, and warn about them, scams are everywhere, and I get messages from people who are receiving scams almost every week. Tip #1 for avoiding trademark scams is know your registration renewal dates. Many scams try to get you to renew your trademark long before it’s even possible, so if you know the renewal dates, you can avoid those.

Trademark 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

3 Count: Sign of the Times

Plagiarism Today

New York Times files lawsuit against Microsoft and OpenAI, Strike 3 Holdings breaks previous year's record and Star Wash draws lawsuit. The post 3 Count: Sign of the Times appeared first on Plagiarism Today.

article thumbnail

Artificial Intelligence and Copyright in China: Lessons from a Recent Court Case

Patently-O

by Dennis Crouch Thus far US copyright and patent tribunals have refused to award rights for AI generated works. China has begun its move in the opposite direction with the recent decision granting rights to an artist who created an image using the popular generative AI system Stable Diffusion. The case of Li v. Liu was decided by the recently Beijing Internet Court.

Copyright 139
article thumbnail

Software Composition Analysis: The New Armor for Your Cybersecurity

Speaker: Blackberry, OSS Consultants, & Revenera

Software is complex, which makes threats to the software supply chain more real every day. 64% of organizations have been impacted by a software supply chain attack and 60% of data breaches are due to unpatched software vulnerabilities. In the U.S. alone, cyber losses totaled $10.3 billion in 2022. All of these stats beg the question, “Do you know what’s in your software?

article thumbnail

Trademark Practice in Korea is Changing - What US Companies Should Know and Consider

JD Supra Law

In October, 2023, Korea passed a new trademark law to add flexibility to its strict trademark registration requiring that later-filed marks need to be completely unique from existing senior marks. Under current trademark law in Korea, a later-filed mark that is similar to a senior mark already registered with the Korean Intellectual Property Office (“KIPO”) would be rejected for registration.

Trademark 120
article thumbnail

ACE Has Prepared a Huge List of Pirate Sites it Wants to Shut Down in 2024

TorrentFreak

During the past few hours, users of streaming site ahaseries.com hoping to access their favorite site would’ve met with disappointment. The same also goes for those who attempted to access uhuseries.com and owlserieshd.com. All three domains are now under the control of the Motion Picture Association, which in turn is directing visitors to the web portal of the Alliance for Creativity and Entertainment (ACE).

More Trending

article thumbnail

The Year in Review: Top Ten Michael Geist Substacks

Michael Geist

My look back at 2023 concludes with a review of my most popular Substacks of the year. Given the overlap between blog posts and Substacks, there is unsurprisingly overlap between the most popular posts with the piece on Bill S-210 occupying the top spot on both charts. However, there are differences, with posts on the CBC and my appearance before the CRTC that focused on competition and consumer choice making their way into the Substack top ten. 1.

article thumbnail

So Blog, So Good: The Best of 2023

Cogency Global

What this is : From the Corporate Transparency Act to China’s accession to the Hague Apostille Convention, 2023 certainly never gave us a dull moment. We've conveniently rounded up our top 10 most popular articles (based on views) from the year for your perusal. What this means : You could argue that 2023 made 2022 look like 2021 , but then you’d have to go back and read our top 10 articles for each year.

article thumbnail

Protection of Prior Trade Name in the Trademark Right Granting and Verification Proceedings | “TDK” Trademark Opposition Case

JD Supra Law

When the prior trade name has a high reputation, and the goods using the trade name have a strong connection to the designated goods of the opposed mark, especially when the word part of the opposed mark is identical with the prior trade name, the use of the opposed mark is likely to cause confusion and misunderstanding among the relevant public, thus damaging the rights of the prior trade name right, and violating the provisions of Article 31 of the Trademark Law (2001).

article thumbnail

CAFC Says District Court Erred in Claim Construction of ‘Barcode’

IP Watchdog

On December 26, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in K-fee System GmbH v. Nespresso USA, Inc., reversing a claim construction ruling and summary judgment of noninfringement issued by the Central District of California. In construing the claim term “barcode” de novo, the Federal Circuit found that the district court erred in finding that its definition expressly excluded “bit codes” in light of the patent owner’s representations during Europea

Patent 69
article thumbnail

IPO Diversity in Innovation Toolkit

Women and diverse employees have the technical skill and knowledge, yet their contributions are not patented at the same rate as those of their male counterparts.This toolkit can help organizations move the needle on achieving gender parity in innovation.

article thumbnail

Breaking: Judgment in Regeneron v. Mylan (aflibercept) BPCIA Case Finding Some Claims of Asserted Patents Valid and Infringed

JD Supra Law

As previously reported by Big Molecule Watch, trial in Regeneron’s BPCIA case against Biocon regarding Biocon’s proposed aflibercept biosimilar concluded on June 15, 2023 in the Northern District of West Virginia. The patents-at-issue are directed to formulations and dosing regimens for aflibercept, an anti-VEGF treatment for retinal disorders including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

Patent 73
article thumbnail

Trademark Influencers and Aspen Mountain

Patently-O

by Dennis Crouch I’m excited to head out to Snowmass in early January for the IP-SKI conference! Although we have the Ozarks here in mid-Missouri, there is nothing like the Rocky Mountains. This year I’ll also have the opportunity once again to connect with other intellectual property lawyers and talk shop while enjoying some long runs. ( LINK ) In the meantime, I came across an interesting lawsuit that Aspen Skiing Company (ASC) recently filed against ski apparel company Perfect Mo

article thumbnail

UCB, Inc. v. Annora Pharma Priv. Ltd. - Briviact® (Brivaracetam)

JD Supra Law

Case Name: UCB, Inc. v. Annora Pharma Priv. Ltd., Civ. No. 20-987-CFC, 2023 WL 5274566 (D. Del. Aug. 16, 2023) (Connolly, J.) - Drug Product and Patent(s)-in-Suit: Briviact® (brivaracetam); U.S. Patent No. 6,911,461 (“the ’461 patent”).

Patent 73
article thumbnail

identical product labeled "For children" and sold at higher price could be deceptive

43(B)log

Mendoza v. Procter & Gamble Co., No. CV 23-1382-DMG (JPRx), 2023 WL 8860900 (C.D. Cal. Dec. 20, 2023) Mendoza brought the usual California claims , alleging that Vicks Vapo cough and cold treatment products marketed as being for children were identical to the adult versions, only pricier; the court mostly rejected P&G’s motion to dismiss. The Children’s VapoRub front label states that it is for children two and older; the Standard Product’s front label includes no age instruction.

article thumbnail

FDA Approves Another Interchangeable Biosimilar

JD Supra Law

Earlier this year, the U.S. Food and Drug Administration announced approval of Amgen's Wezlana (ustekinumab-auub) as an interchangeable biosimilar to Janssen Biotech's Stelara (ustekinumab). The drug was approved for multiple inflammatory disorders.

73
article thumbnail

Sellout!

Likelihood of Confusion

Yes, we’ve added Google ads (o’er on the right side). We generate a decent amount of traffic here, especially off searches relating to trademark law, and especially one very special. The post Sellout! appeared first on LIKELIHOOD OF CONFUSION™.

article thumbnail

The Similarity of Foreign Language Trademarks should be Judged Based on the Common Understanding of the Relevant Public in China | Opposition Appeal Case Regarding the Trademark “?????”

JD Supra Law

The basic function of a trademark is to enable consumers to identify goods and their source. When the disputed trademark is a foreign language sign, the people's court shall, based on the common understanding of the relevant public in China, examine and determine whether the foreign language trademark has distinctive features. Similarly, when judging the similarity of a foreign language trademark, the standard should also be based on the common understanding of the relevant public in China.

article thumbnail

The Tweet days of summer

Likelihood of Confusion

Some summer! If it’s not broiling it’s flooding. Just try a vacation in this nonsense. Speaking of nonsense, here’s topical tweeting that went out via @roncoleman in the last few. The post The Tweet days of summer appeared first on LIKELIHOOD OF CONFUSION™.

59
article thumbnail

The Time Node for Judging Whether the Prior Right Exists is the Date of Approval for Registration at the Latest | “??” (Xiang Qiu in Chinese) Trademark Invalidation Case

JD Supra Law

When applying for a trademark, the trademark owner shall not prejudice the prior rights of others, and shall fulfill the obligation of reasonable avoidance. However, considering that the trademark right has not been acquired at the time of application, the judicial interpretation, in combination with the practical situation, extended the effective time node of the prior right from the application date to the date of approval for registration at the latest, that is, the time node for judging.

article thumbnail

Trade Secrets in 2023 Part II: Identification, Misappropriation and Remedies

IP Watchdog

In Part I of this article, we recapped some of the most notable trade secret cases of the past year that dealt with issues such as proving secrecy and exercising reasonable efforts, as well as the publication of a key judicial resource for trade secret cases. Below, we continue with some of the top trade secret cases and subject matter the courts addressed in 2023.

article thumbnail

German Court Invalidates CureVac Patent in Ongoing BioNTech Lawsuit

JD Supra Law

On December 19, a German court invalidated CureVac’s messenger RNA technology patent, EP 1 857 122 B1, in a lawsuit brought by CureVac against its rival BioNTech.

Patent 70
article thumbnail

Apple Watches Back on Sale After CAFC Grants Interim Stay of ITC Order

IP Watchdog

Yesterday, the U.S. Court of Appeals for the Federal Circuit (CAFC) stayed the International Trade Commission’s (ITC’s) October 26 Limited Exclusion Order (LEO) against certain Apple Watches that the ITC found infringed on two Masimo patents that covered technology related to reading blood-oxygen levels. The CAFC does not appear to have published the order on its public website but it is widely available online.

article thumbnail

Penumbra Illuminates Priority Dates Pre and Post-AIA

JD Supra Law

USPTO Director Kathi Vidal recently designated precedential section II.E.3 of Penumbra, Inc. v. RapidPulse, Inc. and clarified that the priority analysis for an AIA reference patent as prior art is different than for a pre-AIA reference patent. USPTO, Director Vidal designates decision as precedential, USPTO (November 15, 2023).

Art 65
article thumbnail

IPKat Book of the Year Awards 2023 - reminder!

The IPKat

Readers are reminded that they can vote for their favourite intellectual property law books of 2023 in the annual IPKat Book of the Year Awards! Votes must be made via email before 15th January 2024 as per the instructions below. As always, readers can vote for books in five categories: Patents, Copyright (including related rights and performers’ rights), Trade Marks (including Geographical Indications), Designs and Intellectual Property (any book that covers more than one type of IP).

article thumbnail

Apple Watch Import Ban Put On Hold By Fed. Circ.

IP Law 360

The Federal Circuit on Wednesday temporarily suspended a U.S. International Trade Commission ruling that banned imports of the Apple Watch in a patent dispute with Masimo Corp.

Patent 52
article thumbnail

Interview, Interview, Interview! Part 3: Conducting the Examiner Interview

LexBlog IP

Prosecuting a patent application may be viewed as a negotiation. The practitioner’s objective: to obtain the desired claim scope for your client; minimize amendments/arguments that might reduce the scope of literal claim coverage or even claim coverage under the doctrine of equivalents; and conclude prosecution in the shortest possible time. The examiner’s primary objective: to protect the public interest by issuing valid U.S. patents; the examiner is not thinking down the road about

article thumbnail

Year in Review: Top Deals in 2023

JD Supra Law

According to PWC, “2023 was a reasonably strong year for the pharmaceutical and life sciences sector with both deal value and volume of M&A close to pre-pandemic levels.” Below is a recap of the top M&A deals in 2023 that focus on biologics and biosimilars and were covered on the Big Molecule Watch.

70
article thumbnail

A Step Too Far? Governor Hochul Vetoes New York Non-Compete Ban

LexBlog IP

New York Governor Kathy Hochul vetoed Senate Bill S3100A , a bill passed by both houses of the legislature in June, that would prohibit all non-compete agreements. This is a significant and interesting end to a year of upheaval in the world of non-compete agreements and other restrictive covenants. Read more.

article thumbnail

REALITY COMPOSER and REALITY CONVERTER Merely Descriptive of Augmented Reality Software, Says TTAB

The TTABlog

Oppositions based on Section 2(e)(1) mere descriptiveness are somewhat rare. Here's a consolidated opposition in which the Board found the proposed marks REALITY COMPOSER and REALITY CONVERTER to be merely descriptive of Apple's downloadable software that converts files and assists in composing scenes in augmented reality. The Board relied on "the plain meaning of the words in connection with Applicant’s software products that have the functions and purposes of converting and composing" as suffi

article thumbnail

German Court Invalidates CureVac Patent in Ongoing BioNTech Lawsuit

LexBlog IP

On December 19, a German court invalidated CureVac’s messenger RNA technology patent, EP 1 857 122 B1, in a lawsuit brought by CureVac against its rival BioNTech. CureVac, a biopharmaceutical company developing messenger RNA therapeutics for COVID-19 vaccines, announced that it will appeal the decision before the German Federal Court of Justice.

Patent 52
article thumbnail

Breaking: Judgment in Regeneron v. Mylan (aflibercept) BPCIA Case Finding Some Claims of Asserted Patents Valid and Infringed

LexBlog IP

As previously reported by Big Molecule Watch, trial in Regeneron’s BPCIA case against Biocon regarding Biocon’s proposed aflibercept biosimilar concluded on June 15, 2023 in the Northern District of West Virginia. The patents-at-issue are directed to formulations and dosing regimens for aflibercept, an anti-VEGF treatment for retinal disorders including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

Patent 52
article thumbnail

Year in Review: Top Deals in 2023

LexBlog IP

According to PWC , “2023 was a reasonably strong year for the pharmaceutical and life sciences sector with both deal value and volume of M&A close to pre-pandemic levels.” Below is a recap of the top M&A deals in 2023 that focus on biologics and biosimilars and were covered on the Big Molecule Watch. Coya Announces Agreement with Dr.